(Q37980179)

26 August 2017

Atazanavir: in pediatric patients with HIV-1 infection (English)

1 reference

26 August 2017

1 reference

1

Emma D Deeks

1 reference

26 August 2017

1 April 2012

1 reference

26 August 2017

1 reference

26 August 2017

14

1 reference

26 August 2017

131-141

1 reference

26 August 2017

2

1 reference

https://scigraph.springernature.com/pub.10.2165/11208550-000000000-00000

26 August 2017

0 references

cites work

PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection

1 reference

https://api.crossref.org/works/10.2165%2F11208550-000000000-00000

Impact of antiretroviral therapy on growth, body composition and metabolism in pediatric HIV patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208550-000000000-00000

Atazanavir: a review of its use in the management of HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208550-000000000-00000

Atazanavir: a review of its use in the management of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208550-000000000-00000

BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208550-000000000-00000

In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208550-000000000-00000

Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208550-000000000-00000

Distinct cross-resistance profiles of the new protease inhibitors amprenavir, lopinavir, and atazanavir in a panel of clinical samples

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208550-000000000-00000

Activities of atazanavir (BMS-232632) against a large panel of human immunodeficiency virus type 1 clinical isolates resistant to one or more approved protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208550-000000000-00000

The genotypic inhibitory quotient: a predictive factor of atazanavir response in HIV-1-infected treatment-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208550-000000000-00000

Factors predictive of virological failure on atazanavir in 310 HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208550-000000000-00000

Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208550-000000000-00000

Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208550-000000000-00000

Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208550-000000000-00000

Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208550-000000000-00000

Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208550-000000000-00000

Model-based approach for optimization of atazanavir dose recommendations for HIV-infected pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208550-000000000-00000

HIV-Infected Adolescents: Relationship Between Atazanavir Plasma Levels and Bilirubin Concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11208550-000000000-00000

Change to a once-daily combination including boosted atazanavir in HIV-1-infected children

21 January 2018

1 reference

12 December 2020

Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients

1 reference

12 December 2020

Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study

1 reference

12 December 2020

Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia

1 reference

12 December 2020

10.2165/11208550-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

22292486

Dimensions Publication ID

26 August 2017

1003541090

0 references

Fatcat ID

release_ti5tkdvoejc4zjsikzitpswvgq

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ti5tkdvoejc4zjsikzitpswvgq

24 November 2022

mapped directly with Wikidata item

PubMed ID

22292486

1 reference

PubMed ID

22292486